AMWL — American Well Corporation

Amwell (AMWL) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $54.9 million, down 18% year-over-year.
• Subscription Revenue: $24.9 million, down 23% year-over-year due to churn, though renewals exceeded expectations.
• Amwell Medical Group (AMG) Visit Revenue: $28.9 million, up 9% year-over-year, with paid visits totaling approximately 382,000.
• Total Platform Visits: 1 million, down 19% year-over-year.
• Gross Profit: $28 million with a gross margin of 51%, down from 52.8% in Q1 2025.
• Operating Expenses: $45.4 million, down 31% year-over-year; improved as a percentage of revenue to 82.6%.
• Adjusted EBITDA: Loss of $3.1 million, an improvement from a loss of $12.2 million in Q1 2025.
• Cash Position: $179 million in cash and investments, with no debt; cash burn reduced to $3.1 million from $19 million in the previous quarter.

2. Strategic Updates and Business Highlights

• Amwell has focused on consolidating its platform to meet urgent customer needs, resulting in a renewed three-year contract with Elevance and a global deployment with the DHA.
• The company aims to leverage AI and a unified data structure to enhance operational efficiency and improve clinical outcomes.
• Significant operational improvements have been made, including a shift towards higher-margin SaaS offerings, which is expected to support margin expansion.
• The regulatory environment is favorable, with CMS making telehealth flexibilities permanent, which is a tailwind for Amwell’s platform.

3. Forward Guidance and Outlook

• Q2 2026 Revenue Guidance: Expected between $48 million and $52 million, with an adjusted EBITDA loss projected between $4 million and $2 million.
• Full Year 2026 Revenue Guidance: Reiterated at $195 million to $205 million, with an updated adjusted EBITDA loss forecast of $16 million to $12 million (previously $24 million to $18 million).
• Confidence in achieving positive cash flow from operations by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Total revenue and subscription revenue declined year-over-year, primarily due to churn, which remains a concern.
• Visit volumes were down compared to the previous year, although there was a positive trend in higher-value care.
• The company faces challenges with vendor sprawl and the integration of point solutions, which complicates customer experiences.
• Competitive pressures exist as customers are cautious about adopting AI features, preferring proven aspects of the platform.

5. Notable Q&A Insights

• Discussions around the DHA contract renewal indicated confidence in maintaining the relationship, with expectations for potential expansion in behavioral health services.
• The pipeline for new opportunities is significantly larger than in previous years, with a focus on government contracts.
• AI capabilities are increasingly discussed with clients, but the willingness to pay for these features varies, with many clients preferring to bundle them within existing platform pricing.
• Management expressed optimism about future revenue growth in 2027, driven by new government contracts and a stable operational cost structure.

Overall, Amwell's Q1 2026 results reflect a mix of challenges and strategic progress, with a focus on improving financial metrics and expanding its market presence through a unified platform and AI capabilities.